Abstract: There are currently no effective biomarkers to select chemotherapy, immunotherapy, and radiotherapy for treating lung cancer patients. This study identified genetic networks containing major immune-checkpoint inhibitors CD27, PD1, and PDL1, and their associated prognostic genes and proliferation genes in lung cancer tumors. A co-expression network that was missing in tumor B cells was discovered that can promote lung cancer proliferation. A 5-gene and a 9-gene prognostic models were developed and validated in extensive cohorts to select patients at a high risk for developing metastasis. CRISPR-Cas9 and RNA interference screening data were used in the selection of proliferation genes. These genes were associated with chemoresponse and radio-therapy response in lung cancer cell lines and patient tumors. These immune-omics networks led to the discovery of repositioning drugs for improving lung cancer treatment.

Abstract: This invention identifies sets of microRNAs (miRNAs) that classified breast cancer or lung cancer tumors from normal lung tissues with a high accuracy in patients. The findings also allowed identification of methods for improving lung or breast cancer diagnosis, optimizing treatment selection, and discovering new drug options for better patient outcomes.

Abstract: This invention provides a method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of PD-198306 or pharmaceutically acceptable salts thereof, U-0126 or pharmaceutically acceptable salts thereof, ZM-306416 or pharmaceutically acceptable salts thereof, and PQ-401 or pharmaceutically acceptable salts thereof, for treating non-small cell lung cancer in said patient. This invention provides a method for producing an immune response in a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of PD-198306, U-0126, ZM-306416, and PQ-401, for producing an immune response in said patient.

Abstract: A method of making a pre-stretched plastic packaging film comprising co-extruding a top layer, a bottom layer, and a core layer into a multilayer film intermediate product, wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene resin, and the core layer comprises polyethylene resin and filler particles; stretching the multilayer film intermediate product to impart cavitation in the core layer in the area of the filler particles to form a pre-stretched polyethylene-based film; and rolling the pre-stretched polyethylene-based film onto a roller to form a roll of pre-stretched polyethylene-based film. A multilayer pre-stretched plastic packaging film comprising: a core layer sandwiched between a top layer and a bottom layer wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene, and the core layer comprises filler particles having a particle size of 0.1 to 20 ?m in a polyethylene-based matrix comprising at least about 95 wt % polyethylene.

Abstract: A method of providing a treatment to a patient having non-small cell lung cancer is provided comprising extracting total RNA from a formalin fixed and paraffin embedded tumor of non-small cell lung cancer of a patient after the surgical resection, generating complementary DNA (cDNA) of the extracted total RNA from the patient's tumor, quantifying of mRNA expression of 7 genes of ABCC4 (SEQ ID NO:1), CCL19 (SEQ ID NO:2), SLC39A8 (SEQ ID NO:3), CD27 (SEQ ID NO:4), FUT7 (SEQ ID NO:5), ZNF71 (SEQ ID NO:6), and DAG1 (SEQ ID NO:7), normalizing of the quantification of the 7 genes with the quantification of a control gene UBC (SEQ ID NO:8) or a housekeeping gene, and utilizing the normalized 7 gene mRNA expression quantification to determine whether the patient will benefit from receiving adjuvant chemotherapy or not.

Abstract: A method of making a pre-stretched plastic packaging film comprising co-extruding a top layer, a bottom layer, and a core layer into a multilayer film intermediate product, wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene resin, and the core layer comprises polyethylene resin and filler particles; stretching the multilayer film intermediate product to impart cavitation in the core layer in the area of the filler particles to form a pre-stretched polyethylene-based film; and rolling the pre-stretched polyethylene-based film onto a roller to form a roll of pre-stretched polyethylene-based film. A multilayer pre-stretched plastic packaging film comprising: a core layer sandwiched between a top layer and a bottom layer wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene, and the core layer comprises filler particles having a particle size of 0.1 to 20 ?m in a polyethylene-based matrix comprising at least about 95 wt % polyethylene.

Abstract: A method of providing a treatment to a patient having non-small cell lung cancer is provided comprising extracting total RNA from a tumor of non-small cell lung cancer of a patient after the surgical resection, generating complementary DNA (cDNA) of the extracted total RNA from the patients tumor, quantifying of mRNA expression of 7 genes of ABCC4 (SEQ ID NO:1), CCL19 (SEQ ID NO:2), SLC39A8 (SEQ ID NO:3), CD27 (SEQ ID NO:4), FUT7 (SEQ ID NO:5), ZNF71 (SEQ ID NO:6), and DAG1 (SEQ ID NO:7), normalizing of the quantification of the 7 genes with the quantification of a control gene UBC (SEQ ID NO:8), and utilizing the normalized 7 gene mRNA expression quantification to determine whether the patient will benefit from receiving adjuvant chemotherapy or not.

Abstract: A method of making a pre-stretched plastic packaging film comprising co-extruding a top layer, a bottom layer, and a core layer into a multilayer film intermediate product, wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene resin, and the core layer comprises polyethylene resin and filler particles; stretching the multilayer film intermediate product to impart cavitation in the core layer in the area of the filler particles to form a pre-stretched polyethylene-based film; and rolling the pre-stretched polyethylene-based film onto a roller to form a roll of pre-stretched polyethylene-based film. A multilayer pre-stretched plastic packaging film comprising: a core layer sandwiched between a top layer and a bottom layer wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene, and the core layer comprises filler particles having a particle size of 0.1 to 20 ?m in a polyethylene-based matrix comprising at least about 95 wt % polyethylene.

Abstract: A method of making a pre-stretched plastic packaging film comprising co-extruding a top layer, a bottom layer, and a core layer into a multilayer film intermediate product, wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene resin, and the core layer comprises polyethylene resin and filler particles; stretching the multilayer film intermediate product to impart cavitation in the core layer in the area of the filler particles to form a pre-stretched polyethylene-based film; and rolling the pre-stretched polyethylene-based film onto a roller to form a roll of pre-stretched polyethylene-based film. A multilayer pre-stretched plastic packaging film comprising: a core layer sandwiched between a top layer and a bottom layer wherein the top layer and bottom layer comprise at least about 95 wt % polyethylene, and the core layer comprises filler particles having a particle size of 0.1 to 20 ?m in a polyethylene-based matrix comprising at least about 95 wt % polyethylene.

Abstract: Photovoltaic devices are described including: a region of perovskite material which is in electrical contact with a mesoporous region of hole transport material, wherein the hole transport material is at least partially comprised of an inorganic hole transport material.

Abstract: Methods of assessing genomic instability in breast cancer tissue by measuring the expression level of genes CDKN2A, SCYA18, STK15, NXF1, cDNA Dkfzp762M127, p28 KIAA0882, MYB, Human clone 23948, RERG, HNF3A, and ACADSB or a nucleic acid sequence comprising about 90% or greater sequence identity to SEQ ID NO: 21 in breast cancer tissue, an array suitable for use in such methods, and related methods and compositions.

Abstract: A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. Another embodiment is a method to determine relapse free potential in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and a 24-gene signature, and developing a quantitative expression profile.

Abstract: A non-small cell lung cancer postoperative survival prognosticator comprising a detection mechanism consisting of 15-gene, 12-gene, and 16-gene signature and methods of use. Also provided are the identification of various subsets from the 25 prognostic signature genes with potential of operative survival prognosticator for non-small cell lung cancer patients in all tumor stage and early stage and potential for chemoresponse with a method of use.

Abstract: A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. A second embodiment is a method to determine metastatic potential, relapse potential, or both in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and either the 15, 23, or 28-gene signatures, and developing a quantitative expression profile. Utilizing risk analysis the individual can be placed into one of two or more groups predicting risk and/or clincopathogic variables.

Abstract: A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. A second embodiment is a method to determine metastatic potential, relapse potential, or both in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and either the 15, 23, or 28-gene signatures, and developing a quantitative expression profile. Utilizing risk analysis the individual can be placed into one of two or more groups predicting risk and/or clincopathogic variables.

Abstract: Methods of assessing genomic instability in breast cancer tissue by measuring the expression level of genes CDKN2A, SCYA18, STK15, NXF1, cDNA Dkfzp762M127, p28 KIAA0882, MYB, Human clone 23948, RERG, HNF3A, and ACADSB or a nucleic acid sequence comprising about 90% or greater sequence identity to SEQ ID NO: 21 in breast cancer tissue, an array suitable for use in such methods, and related methods and compositions.

Abstract: A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. A second embodiment is a method to determine metastatic potential, relapse potential, or both in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and either the 15, 23, or 28-gene signatures, and developing a quantitative expression profile. Utilizing risk analysis the individual can be placed into one of two or more groups predicting risk and/or clincopathogic variables.

Abstract: The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

Abstract: A first embodiment is a non-small cell lung cancer recurrence prognosticator comprising a detection mechanism consisting a 35-gene signature. A second embodiment is a non-small cell lung cancer tumor stage prognosticator comprising a detection mechanism consisting an 11-gene signature. A third embodiment is a non-small cell lung cancer differentiation prognosticator comprising a detection mechanism consisting an 18-gene signature.

Abstract: The present invention is drawn to a high power electrochemical energy storage device in a bipolar configuration, comprising at least n stackable cells in bipolar configuration wherein subgroups of m cells are electronically monitored. The storage cells have a lithium ion insertion anode and a lithium ion insertion cathode, a separator, an electrolyte system, and a leak-proof seal structure. A number of embodiments are disclosed, characterized by a favorable range of m values, in combination with the anode-to-cathode capacity ratio, electrolyte conductivity, and other battery key features, thereby providing a high power device providing long cycle life and excellent power performance over many thousand charge and discharge cycles while minimizing the cost for electronic monitoring.